Demonstration of Conformational Changes Associated with Activation of the Maltose Transport Complex*

Daynene E. ManneringDagger, Susan Sharma, and Amy L. Davidson§

From the Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030

Received for publication, December 26, 2000, and in revised form, January 8, 2001



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In Escherichia coli, interaction of a periplasmic maltose-binding protein with a membrane-associated ATP-binding cassette transporter stimulates ATP hydrolysis, resulting in translocation of maltose into the cell. The maltose transporter contains two transmembrane subunits, MalF and MalG, and two copies of a nucleotide-hydrolyzing subunit, MalK. Mutant transport complexes that function in the absence of binding protein are thought to be stabilized in an ATPase-active conformation. To probe the conformation of the nucleotide-binding site and to gain an understanding of the nature of the conformational changes that lead to activation, cysteine 40 within the Walker A motif of the MalK subunit was modified by the fluorophore 2-(4'-maleimidoanilino)naphthalene-6-sulfonic acid. Fluorescence differences indicated that residues involved in nucleotide binding were less accessible to aqueous solvent in the binding protein independent transporter than in the wild-type transporter. Similar differences in fluorescence were seen when a vanadate-trapped transition state conformation was compared with the ground state in the wild-type transporter. Our results and recent crystal structures are consistent with a model in which activation of ATPase activity is associated with conformational changes that bring the two MalK subunits closer together, completing the nucleotide-binding sites and burying ATP in the interface.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The periplasmic binding protein-dependent maltose transport system of Escherichia coli is a member of the ATP-binding cassette or ABC1 superfamily of proteins. Members of this protein family are responsible for the transport of a variety of substrates across membranes in both prokaryotic and eukaryotic organisms (1, 2). Medically important members of the superfamily include the multidrug-resistant P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (3, 4). A soluble maltose-binding protein (MBP) and a membrane-spanning transport complex consisting of one MalF, one MalG, and two MalK (MalFGK2) protein subunits mediate maltose transport across the cytoplasmic membrane. The hydrophobic MalF and MalG proteins are predicted to form a transmembrane channel for substrate, and ATP hydrolysis by the associated MalK subunits is coupled to the translocation event (5, 6).

Periplasmic binding proteins bind their substrates tightly and are responsible for the high affinity of this class of prokaryotic transporters (7). In the presence of ligand, the binding proteins undergo a conformational change (8, 9) and initiate translocation by stimulating the ATPase activity of the membrane-bound transporters (10). We have recently demonstrated that MBP activates the ATPase activity of MalFGK2 by stabilizing the transition state for ATP hydrolysis, and as a consequence becomes tightly bound to the transport complex in the presence of the transition state analogue vanadate (11). Vanadate traps ADP in one of the two nucleotide-binding sites, locking the transport complex in the transition state conformation (11, 12). Maltose is likely passed from MBP to MalFGK2 in the transition state, thereby coupling transport to ATP hydrolysis. Mutations have been isolated in MalF and MalG that permit maltose transport in the absence of MBP, albeit with lowered affinity (7). These binding protein-independent (BPI) transport complexes have gained the ability to hydrolyze ATP in the absence of MBP (14). We propose that the BPI mutants function by stabilizing the transport complex in a conformation that is associated with the activation of the ATPase activity of the WT. If the WT and BPI complexes represent the ground state and an active state of the transport complex, respectively, detection of conformational differences between the two complex types could provide information about the transport mechanism.

The fluorescence of the sulfhydryl-specific reagent MIANS is sensitive to the polarity of its environment (15, 16) and has been used to detect conformational changes in the Na+,K+-ATPase (15), the myosin ATPase (17), the P-glycoprotein (18, 19), and the lactose permease (20, 21). In this study, we used MIANS to detect conformational differences in the nucleotide-binding sites of WT and BPI complexes in the ground state and in the transition state to gain further insight into the mechanism of activation of MalFGK2 ATPase activity. We found that the conformation of the nucleotide-binding sites in the BPI complex more closely resembles the transition state than the ground state of the WT complex. Furthermore, the conformational change associated with activation of the ATPase activity relocates residues involved in nucleotide binding to a less surface-exposed environment.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial Strains, Plasmids, and Culture Conditions-- Strain HN741 (Escherichia coli K-12 argH his rpsL1 malT (Con) malBDelta 13 Delta atpBC ilv::Tn10/F' lacIq Tn5) (14) was transformed with the plasmid pMS421 harboring the lacIq gene (22) and two additional plasmids, harboring the malF, malG (pFG23), and malKht (pSS733) genes under control of Ptrc. The malKht gene is a variant of malK encoding six histidines at the 5' end that are used for purification of the transport complex (23). Both wild-type malF (pFG23) and a malF500 (pFG42) allele that imparts a binding protein-independent (BPI) phenotype (7) were used. In some experiments, the pSS733 plasmid carrying the malKht allele was replaced with pSSGly, carrying a cysteine to glycine substitution at a position corresponding to position 40 of the native MalK protein. Plasmid pSSGly was constructed by cloning the RsrII-MluI fragment of pGly, containing the malK C40G mutation ((24) kindly provided by H. Shuman), into pSS751 (malKht K42N) (23) that had been digested with RsrII and MluI. Cells were grown as described previously (12). The total membrane fraction was isolated as described previously (14) and stored at -70 °C until use.

Protein Purification-- Histidine-tagged transport complexes were purified by affinity chromatography as published previously (23) with modifications. Briefly, thawed membrane vesicles were washed by dilution in 20 mM HEPES (pH 8), 1 mM EDTA and collected by centrifugation at 100,000 × g for 30 min. Vesicles were resuspended at a protein concentration of ~3 mg/ml in 50 mM NaPi (pH 8), 10% glycerol, and membrane proteins were solubilized by the addition of n-dodecyl beta -D-maltoside to a final concentration of 1%. Solubilized proteins were bound to a Talon metal affinity column (CLONTECH) equilibrated with "buffer A" at pH 8 (containing 50 mM NaPi, 300 mM NaCl, 10% glycerol, and 0.01% dodecyl maltoside). The column was washed with buffer A at pH 8 and then with buffer A at pH 7. The transport complexes were eluted from the resin with 100 mM histidine in buffer A at pH 7. Purified complexes were extensively dialyzed against "buffer B" (containing 20 mM NaPi (pH 8), 10% glycerol, 5 mM MgCl2, and 0.01% dodecyl maltoside) supplemented with 1 mM EDTA.

MIANS Modification and ATP Protection Studies-- 2-(4'-Maleimidylanilino)naphthalene-6-sulfonic acid (MIANS) was purchased from Molecular Probes, Inc. (Eugene, OR). For MIANS modification studies, transport complexes were labeled in detergent solution (buffer B) by incubation at 25 °C with either 5 or 20 µM MIANS added from a 0.2 mM stock solution in methanol. Complexes that had been reconstituted into proteoliposome vesicles by dilution (6) were labeled in buffer containing 20 mM NaPi (pH 8) and 10 mM MgCl2 at 37 °C (26). In control incubations methanol was added to complexes to the same percent volume as the MIANS stock solution. For ATP protection experiments, complexes were briefly preincubated with ATP as specified in the figure legends before the MIANS was added. Following incubation for 15 min at the specified temperature, reactions were terminated with 1 mM DTT, and complexes were assayed for ATPase activity.

Assays of ATP Hydrolysis-- ATP hydrolysis activity of detergent-soluble and reconstituted transport complexes was measured using [gamma -32P]ATP (Amersham Pharmacia Biotech) as described previously (12, 27). ATP hydrolysis activity of complexes in proteoliposome vesicles was measured at 37 °C in 50 mM HEPES (pH 7) with 2 mM ATP, 10 mM MgCl2, 5 µM MBP, and 0.1 mM maltose using a modification of the technique of Liu et al. (26).

Fluorescence Measurements-- For fluorescence studies, transport complexes were incubated with MIANS for 15 min at 4 °C. Excess MIANS was removed from the protein sample using a HiTrap desalting column (Amersham Pharmacia Biotech). Fluorescence measurements were made using an ISS PC1 Photon Counting Spectrofluorometer (Champaign, IL). Fluorescence spectra for MIANS reacted with beta -mercaptoethanol (MIANS-beta -ME), and MIANS-labeled proteins in buffer B were recorded using an excitation wavelength of 340 nm and an emission range of 360-600 nm. Solvent accessibility was judged by the ability of acrylamide or p-xylene-bispyridinium bromide (DPX, Molecular Probes, Inc.) to quench the fluorescence of MIANS. For fluorescence quenching titrations, additions were made from 1 and 5 M acrylamide stock solutions or from a 0.5 M DPX stock solution. Quenching was monitored at a constant excitation wavelength of 340 nm and an emission wavelength corresponding to the emission maximum of the sample. Fluorescence values were corrected for dilution by performing control titrations with H2O instead of quencher, and the inner filter effect for acrylamide and DPX at the wavelengths used was negligible. The titration data were used to construct Stern-Volmer plots and KSV values calculated according to Lakowicz (28). The Stern-Volmer Equation (1) is as follows,


F<SUB>0</SUB>/F=1+k<SUB>q</SUB>&tgr;<SUB>0</SUB>[Q]=1+K<SUB><UP>SV</UP></SUB>[Q] (Eq. 1)
where F0 is the fluorescence intensity in the absence of quencher; F is the fluorescence intensity in the presence of quencher; kq is the bimolecular quenching constant; [Q] is the concentration of the quencher; tau 0 is the lifetime of the fluorophore in the absence of quencher; and KSV is the Stern-Volmer quenching constant. A plot of F0/F versus [Q], the extent of quenching as a function of acrylamide or DPX concentration, yields a line with slope KSV, a measurement of the accessibility of the fluorophore to solvent.

Preparation of Vanadate-trapped Complexes for Solvent Accessibility Studies-- WT and BPI complexes were treated with vanadate in detergent solution as described previously (11) with modifications. Briefly, reactions contained either 2.5 µM WT or BPI transport complex in buffer B containing 4 mM ATP; 5 µM MBP and 0.01 mM maltose were also included in the WT reactions as specified in the figure legends. Vanadate was added to a final concentration of 0.5 mM where indicated, and the reactions were incubated for 20 min at 37 °C. The samples were then desalted using a Hitrap column and labeled with MIANS as described above. Stable association of MBP with the trapped WT complexes was confirmed using ion-exchange chromatography and SDS-PAGE (11).

Electrophoresis-- SDS-polyacrylamide gel electrophoresis was performed with 11% polyacrylamide gels using the procedure described by Laemmli (29). Fluorescent bands on gels were visualized in 5% methanol, 7.5% acetic acid (17) over an ultraviolet light source and recorded using a Nucleovision imaging system.

Protein Determinations-- Protein concentrations were determined as described previously (6) using the method of Schaffner and Weissmann (30).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Specific Modification of MalK Residue Cys-40 by MIANS-- In an effort to detect conformational changes associated with activation of the ATPase activity of MalFGK2, we wished to modify specifically a cysteine residue in the MalK subunit(s) with a fluorescent reporter group. The MalFGK2 complex contains a total of 10 cysteine residues (three in each MalK, three in MalF, and one in MalG (31-33)), including a reactive cysteine close to the nucleotide-binding site. This residue is located at position 40 (Cys-40) within the Walker A consensus nucleotide-binding motif (also known as the phosphate binding loop, or P-loop) of MalK (34). Modification of this residue by the sulfhydryl-specific reagent N-ethylmaleimide (NEM) inhibits the ATPase activity of the maltose transport complex (35, 36); ATP protects against inhibition (35), and replacement of this cysteine with serine eliminates inhibition without affecting normal activity (37). Based on these findings, we predicted that it would be possible to label covalently Cys-40 with MIANS, a fluorescent maleimide probe that could be used to monitor conformational changes in the MalK subunit. Like NEM, MIANS also inhibited the ATPase activity of both WT and BPI transport systems (Table I). MIANS did not inhibit the ATPase activity of complexes containing a nondeleterious substitution of cysteine with glycine at position 40 in MalK (C40G) (24). These results demonstrate that MIANS reacts with Cys-40 and that modification at this site is responsible for the inhibition of ATPase activity.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Inhibition of MalFGK2 ATPase activity by MIANS
Soluble transport complexes specified in the table were preincubated with methanol or MIANS as described under "Experimental Procedures." In some experiments cysteine 40 (Cys-40) of MalK was replaced with glycine (C40G). Values are the mean ± S.D. of triplicate determinations.

To interpret possible conformational differences detected by MIANS as being associated with Cys-40 in the nucleotide-binding site(s), we assessed the extent of labeling of the other cysteines in the transport complex both by SDS-PAGE and by comparison of the intensity of the fluorescence emission spectra of complexes containing either Cys-40 or a C40G substitution. As seen in SDS-PAGE analysis of MIANS-labeled complexes, very little fluorescence is associated with the MalF and MalG proteins, and substitution of a glycine for the cysteine at position 40 greatly reduces the fluorescence associated with MalK (Fig. 1). The fluorescence emission spectra of the MIANS-labeled WT and BPI complexes revealed that the fluorescence of MIANS associated with C40G complexes was only 10-35% that seen for Cys-40 complexes (Fig. 2). Thus, although residues other than Cys-40 may be modified to some extent, the bulk of the fluorescence is associated with MIANS bound at Cys-40. Variation of buffer, pH, MIANS concentration, and length of incubation did not improve the specificity of the modification reaction (data not shown). Quantitation of MIANS incorporation into MalFGK2 through absorbance measurements at 322 nm (38) failed to address the question of whether residue Cys-40 was modified in one or both MalK subunits (data not shown), in part because of the variability in the background (non-Cys-40) labeling by MIANS. However, based on other observations (see "Discussion"), we hypothesize that only one of the two MalK subunits is modified.



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   MIANS labeling of Cys-40 and C40G complexes. WT transport complexes were labeled with MIANS in detergent solution and analyzed by SDS-PAGE as described under "Experimental Procedures." A, MIANS fluorescence associated with transport complex proteins; B, the same gel stained with Coomassie Blue. Samples were incubated with methanol (odd-numbered lanes) or MIANS (even-numbered lanes) as follows: lanes 1 and 2, Cys-40; lanes 3 and 4, C40G. Arrows indicate the migration positions of (His)6MalK, MalF, and MalG. Molecular weight of standards is indicated in thousands.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Fluorescence spectra of MIANS-labeled complexes. Transport complexes were labeled with MIANS in detergent solution as described under "Experimental Procedures." Fluorescence spectra were recorded using an excitation wavelength of 340 nm and an emission range of 360-600 nm. Fluorescence emission spectra maxima were as follows: a, 0.1 µM MIANS-beta -ME, 443 nm; b, C40G BPI-MIANS, 420 nm; c, C40G WT-MIANS, 421 nm; d, Cys-40 BPI-MIANS, 421 nm; e, Cys-40 WT-MIANS, 431 nm. The small peak at 385 nm is the Raman scatter (28). Protein concentrations were 0.1 µM.

Emission Maximum of BPI Is Blue-shifted Relative to WT-- The fluorescence characteristics of MIANS are sensitive to the hydrophobicity of its environment; specifically, emission maxima are blue-shifted to shorter wavelengths, and the quantum yield increased as the solvent polarity decreases (16, 17). The emission spectra in Fig. 2 were therefore used to compare the local environment of MIANS at Cys-40 in the WT and BPI complexes. For both complexes, MIANS exhibited a greater fluorescence quantum yield when bound to protein than when reacted with beta -mercaptoethanol in solution. The emission maximum of MIANS attached to the WT complex was blue-shifted 12 nm from that of free MIANS-beta -ME, whereas the emission maximum of the BPI complex was blue-shifted 22 nm. These results suggest that the probe is in a more hydrophobic environment when bound to either protein, and the larger blue-shift associated with the BPI complex may indicate that the environment surrounding residue Cys-40 in the nucleotide-binding site is more hydrophobic in the BPI than in the WT.

Solvent Accessibility of Cys-40 in BPI Is Reduced Compared with WT-- To probe further the nature of the conformational difference suggested by the blue shift in the fluorescence emission of the BPI transport complex, collisional quenching experiments were performed to assess the solvent accessibility of MIANS. Specifically, the ability of water-soluble reagents to collide with MIANS and quench its fluorescence was measured as a function of quencher concentration to compare the relative exposure of MIANS in WT and BPI complexes to the aqueous environment. The solvent accessibility of MIANS complexes was assessed using either acrylamide (Fig. 3, A and B) or DPX (Fig. 3, C and D) as a quenching agent. As anticipated, MIANS bound to the complexes was less accessible to the quenching reagents than MIANS free in solution (KSV = 3.18 M-1 for free MIANS-beta -ME in the acrylamide experiments), as judged by the decreased slopes of the lines in the Stern-Volmer plot. In acrylamide quenching experiments, MIANS bound to the WT complex is significantly more exposed to solvent than in the BPI complex, with KSV values of 1.94 and 1.41 M-1, respectively (Fig. 3A). Removal of Cys-40 from both complexes negates this difference, confirming that the assay is reporting on conformational changes located at the nucleotide-binding site. MIANS bound to these C40G complexes was even less exposed to solvent than MIANS at Cys-40 in the BPI transport complex (Fig. 3A). In experiments using DPX, a larger quenching reagent than acrylamide, MIANS bound to the WT complex was also significantly more exposed to solvent than in the BPI complex, with KSV values of 41.5 and 27.3 M-1, respectively. In this case, the exposure of MIANS on the BPI complex to DPX was the same as that seen for the complexes containing the C40G substitution (Fig. 3C). These data provide further evidence of a conformational difference between the WT and BPI complexes which appears to affect the exposure of residues in the nucleotide-binding pocket to the aqueous milieu.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Solvent accessibility of Cys-40 and C40G complexes. Transport complexes containing MalK Cys-40 or C40G subunits were labeled with MIANS in detergent solution and titrated with either acrylamide (A and B) or DPX (C and D) as described under "Experimental Procedures." ATP was present at 1 mM where indicated. The Stern-Volmer plots are as follows. A, , 1 µM MIANS-beta -ME; open circle , C40G BPI-MIANS; +, C40G WT-MIANS; black-square, Cys-40 BPI-MIANS; , Cys-40 WT-MIANS. B, , 1 µM MIANS-beta -ME; open circle , Cys-40 BPI-MIANS; +, Cys-40 BPI-MIANS with ATP; black-square, Cys-40 WT-MIANS; , Cys-40 WT-MIANS with ATP. C, , 1 µM MIANS-beta -ME,; open circle , C40G BPI-MIANS; +, C40G WT-MIANS; black-square, Cys-40 BPI-MIANS; , Cys-40 WT-MIANS. D, , 1 µM MIANS-beta -ME; open circle , Cys-40 BPI-MIANS; +, Cys-40 BPI-MIANS with ATP; black-square, Cys-40 WT-MIANS; , Cys-40 WT-MIANS with ATP. Points are presented as mean values ± S.D. of titrations performed in triplicate.

In experiments similar to those presented here, the fluorescence of MIANS positioned in the P-loop of P-glycoprotein was quenched by ATP in a concentration-dependent manner (18). We therefore added ATP to the labeled MalFGK2 complexes to determine whether nucleotide binding could be detected as a change in the fluorescence properties of MIANS at Cys-40. The presence of 1 mM ATP had no effect on the fluorescence emission spectrum of either transport complex (data not shown) and did not significantly alter solvent accessibility (Fig. 3, B and D) other than a small effect on exposure of the WT to acrylamide. Because ATP protects against modification of residue Cys-40 (35), MIANS might prevent nucleotide binding in the MalFGK2 system via a steric effect. If MIANS modifies only one nucleotide-binding site, it is also possible that ATP binds to one site without significantly altering the fluorescence characteristics of MIANS at the second site.

Detection of Conformational Changes Associated with Attainment of the Transition State for ATP Hydrolysis-- We recently showed that vanadate inhibits MalFGK2 by trapping the complex in its transition state conformation with ADP tightly bound in one of the two nucleotide-binding sites (11, 12). Vanadate-induced nucleotide trapping requires MBP in the WT but not in a BPI mutant (12). The ability to trap the transition state provides a second model system that can be used to study conformational changes associated with activation of ATPase activity. Because vanadate trapping of the transition state conformation requires ATP hydrolysis (12), complexes were first treated with vanadate and then labeled with MIANS. The fluorescence intensity of either the WT or the BPI complex labeled after vanadate treatment was very similar to the intensity of control preparations labeled without the treatment; however, in the WT complex, vanadate treatment resulted in a 3-nm blue shift in fluorescence emission relative to the untreated complex (data not shown). The solvent accessibility of MIANS was then assessed using acrylamide quenching. The accessibility of MIANS in the BPI complex was unchanged by vanadate treatment (Fig. 4). In the WT complexes, addition of MBP in the absence of vanadate did not alter the solvent accessibility of MIANS (Fig. 4). However, the solvent accessibility of MIANS was different when WT complexes were vanadate-trapped in the presence of MBP. The accessibility was reduced to a level resembling that of MIANS bound to BPI complexes, suggesting that the conformation of the BPI may resemble the transition state of the WT transporter.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Solvent accessibility of vanadate-trapped complexes. Transport complexes in the presence or absence of MBP were incubated with or without vanadate as described under "Experimental Procedures," then labeled with MIANS, and titrated with acrylamide Stern-Volmer. Plots were constructed, and the resultant KSV values were as follows: 1, 1 µM MIANS-beta -ME, 3.50 M-1; open circle , BPI-MIANS, 1.31 M-1; +, BPI-MIANS with vanadate, 1.33 M-1; black-square, WT-MIANS, 1.77 M-1; , WT-MIANS with MBP, 1.74 M-1; black-triangle, WT-MIANS with MBP and vanadate, 1.42 M-1. Points are presented as mean values ± S.D. of titrations performed in triplicate.

Another feature of the WT complex trapped in the transition state species is that it binds tightly to MBP (11), whereas in the ground state it displays a relatively low affinity for MBP (39, 40). If the conformation of the BPI transporter resembles the transition state, it might display a high affinity for MBP even in the absence of vanadate, as shown indirectly for another BPI mutant, MalFG511K2 (40). As shown in Fig. 5, MBP is tightly associated with the MalF500GK2 BPI complex, both in the presence and absence of treatment with vanadate, whereas the tight binding interaction is seen for the WT only in the presence of vanadate. This result provides additional evidence that the conformation of the BPI complex resembles the transition state and may in fact represent an intermediate in the pathway from the ground state to the transition state in the WT. As such, further comparison of WT and BPI complexes might provide increased insight into the mechanism of activation of MalFGK2 ATPase activity.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Binding of MBP to MalFGK2. WT MalFGK2 in proteoliposomes was incubated with 10 µM maltose, 5 µM MBP, 15 mM MgCl2, and 5 mM ATP at 37 °C in the presence or absence of 0.5 mM vanadate, as described previously (11). Proteoliposomes were then diluted 20-fold into 20 mM HEPES, 0.1 mM EDTA, collected by centrifugation, resuspended in HEPES, EDTA, and analyzed by Coomassie staining of SDS-polyacrylamide gels. The reconstituted BPI transporter was treated as described for the WT except without maltose and MBP. After washing to remove unbound vanadate, the BPI proteoliposomes were then incubated with 5 µM MBP, 10 µM maltose, and 15 mM MgCl2 for an additional 20 min at 37 °C before being diluted 20-fold into 20 mM HEPES, 0.1 mM EDTA, collected by centrifugation, resuspended in HEPES, EDTA, and analyzed by SDS-PAGE. Lane 1, molecular weight standard; lane 2, BPI without vanadate, MBP added; lane 3, BPI with vanadate, MBP added; lane 4, WT without vanadate; lane 5, WT with vanadate. Arrows indicate the migration positions of (His)6MalK, MalF, MalG, and MBP. Molecular weight of standards is indicated in thousands.

WT and BPI Complexes Differ in Affinity for ATP-- In preliminary experiments, we noted a difference in the ability of ATP to protect against the irreversible modification of the WT and BPI complexes by MIANS (data not shown). To pursue this observation further, the concentration dependence of ATP protection of WT and BPI complexes against modification by either 20 or 5 µM MIANS was examined (Fig. 6, A and B). The concentrations of ATP needed to protect 50% of the complexes against modification, or PC50 values, are summarized in Table II. At the 20 µM MIANS concentration, 30-fold more ATP is required to protect the WT transporters as opposed to the BPI transporters. The same results are obtained at the 5 µM MIANS concentration, although a correspondingly lower concentration of ATP is required to gain the same level of protection. These results suggest that MIANS and ATP compete for binding to MalFGK2 and that the BPI mutant may have a higher affinity for ATP than the WT transporter. In the absence of a reliable assay to measure nucleotide binding to MalFGK2, we estimated the affinity indirectly by measuring the half-saturation constant (K0.5) for ATP hydrolysis by the BPI and WT complexes (Table II). The K0.5 for the BPI transporter was 14-fold lower than the corresponding value for the WT transporter and correlated well with the ability of ATP to protect against MIANS modification. At the lower concentration of MIANS (5 µM) the PC50 values approached the K0.5, suggesting that the differential ability of ATP to protect truly reflects the differential nucleotide binding affinity of the WT and BPI complexes. These data suggest that BPI transporters have a greater affinity for ATP than do WT transporters.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   ATP protection against MIANS modification. Transport complexes in detergent solution were preincubated for 15 s with various concentrations of ATP before addition of MIANS to a final concentration of 20 µM (A) or 5 µM (B). Incubations were terminated after 15 min by addition of 1 mM DTT, and the complexes were assayed for ATP hydrolysis activity: black-square, BPI complexes; open circle , WT complexes. Values for control incubations with methanol are as follows: A, BPI, 730 nmol Pi/mg/min; WT, 200 nmol Pi/mg/min. B, BPI, 820 nmol Pi/mg/min; WT, 70 nmol Pi/mg/min.


                              
View this table:
[in this window]
[in a new window]
 
Table II
ATP protection and kinetic data



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have used an extrinsic fluorescent probe to detect conformational changes in the nucleotide-binding site associated with activation of the MalFGK2 ATPase. In the WT system, the ATPase activity of the MalFGK2 transporter is stimulated through an interaction with maltose-bound MBP that stabilizes the transition state for hydrolysis (11). The need for MBP can be bypassed by mutations (BPI mutations) that result in constitutive activation of the ATPase activity of the transporter (14). A conformational difference between the WT and BPI transport complex, detected in the absence of both MBP and nucleotide, manifested itself both as a change in the position of the emission spectrum maximum and in the solvent accessibility of bound MIANS. The fluorescence of MIANS bound to residue Cys-40 of MalK was blue-shifted in the BPI complexes relative to the WT complexes, indicative of a more hydrophobic environment, and was less accessible to water-soluble quenching agents. These results suggest that residue Cys-40 in the P-loop is shifted to a more buried location in the conformation that is stabilized by the BPI mutations. In the case of the BPI MalF500GK2 complex used in this study, two mutations in the transmembrane region of MalF, G338R and N505I (41), are responsible for the conformational changes in the nucleotide-binding site of the MalK subunit(s) and the activation of the ATPase activity (14).

Because vanadate can be used to lock both the WT and the BPI transporter in the transition state for ATP hydrolysis (11, 12), we also used differences in the fluorescence characteristics of MIANS to compare the ground state and transition state conformations of MalFGK2. When vanadate was used to lock the WT MalFGK2 complex in the transition state, the accessibility of residue Cys-40 in the P-loop was decreased relative to the ground state. This decreased level of accessibility was very similar to the level observed for the ground state of the BPI complex, suggesting that the conformational changes that activate the ATPase activity, whether by interaction with MBP or by mutation, may be similar. In contrast, vanadate trapping of the transition state of the BPI complexes had no effect on the solvent accessibility of MIANS (Fig. 4), suggesting that the environment of residue Cys-40 does not change substantially in the transition from the ground state to the transition state of the BPI transporter. The absence of any effect in the BPI system argues that steric effects of nucleotide trapped by vanadate in one of the two nucleotide-binding sites (11) are not solely responsible for the decrease in solvent accessibility of MIANS in the WT. Since ATP protects against MIANS modification (Fig. 6), we predict that only the unoccupied nucleotide-binding site is modified after vanadate treatment. Since the fluorescence intensity of transporters was the same whether they were labeled before or after vanadate-induced nucleotide trapping, MIANS may modify only one nucleotide-binding site even in the untreated transporter. Modification of a single nucleotide-binding site by 4chloro-7-nitrobenzofurazan-Cl has been demonstrated for P-glycoprotein, where it appears that covalent modification of one site prevents modification of the other site (42).

The similarities in the environment of the nucleotide-binding site in the BPI mutant and in the transition state suggest that the mutations in the BPI transporter have stabilized a conformation that resembles, at least superficially, the conformation of the transition state, thereby overcoming the major requirement for MBP in stabilization of the transition state and therefore activation of the ATPase activity. The observation that the BPI MalF500GK2 complex binds MBP tightly in the absence of vanadate (Fig. 5) strengthens this hypothesis. An increased affinity for MBP may be a general feature of the BPI mutants, since it has been reported that the BPI MalFG511K2 complex also displays a higher affinity for MBP than the WT complex (40).

Knowing that MBP stimulates the ATPase activity of MalFGK2, these results were originally interpreted in terms of an equilibrium between two different conformations of the transporter, an ATPase-inactive conformation that predominates in the WT and the ATPase-active conformation induced through interaction with MBP (40). The BPI mutants were believed to shift this equilibrium in favor of the active conformation, to a lesser or greater extent, accounting for the difference in maximal ATP hydrolysis rates between different BPI mutants (14, 43). Because of induced fit, the active conformation was expected to have a surface more complementary to MBP than the ATPase-inactive state and hence have a higher affinity for MBP (40). With the new knowledge that MBP stimulates ATP hydrolysis by binding tightly to the transition state conformation of the transport complex, we now suggest that the BPI conformations may resemble different intermediates in the pathway of the WT as it approaches the transition state. These conformational states may not be populated to any great extent in the cycle of ATP hydrolysis by the WT, providing an explanation for the failure of MBP to alter noticeably the conformation of MalFGK2 without vanadate present (Fig. 5). Alternatively, although less likely, the inactivation caused by MIANS modification may have prevented attainment of the active conformation.

The increased ability of ATP to protect BPI complexes against MIANS modification as well as the decreased K0.5 for ATP hydrolysis by the BPI complexes indicates that the BPI complexes exhibit an increased affinity for ATP as compared with the WT complexes. If we are correct in assuming that the BPI complex resembles an intermediate in the pathway of the WT, then incremental or ratcheted increases in the affinity for both ATP and MBP may be characteristic of the approach to the transition state for ATP hydrolysis. The affinity of MalFGK2 for ATP would never exceed the affinity for the ATP in its transition state conformation, ensuring that ATP hydrolysis occurs (44). The increased affinity that the BPI complex displays for ATP could also be a by-product of the specific mutations that induced the BPI phenotype and unrelated to the normal pathway of activation of ATPase activity. Analysis of other BPI mutations may resolve this issue.

Recent structural information about ABC proteins aids in the interpretation of these findings. The crystal structures of two nucleotide-binding subunits of ABC transporters are now available, the HisP protein from Salmonella typhimurium (45) and the MalK protein from Thermococcus litoralis (46). These two proteins share a similar architecture as expected from the sequence homology, and the nucleotide-binding site is highly exposed on the surface of the monomer subunit, raising the possibility that residues from another subunit in the transport complex may contribute to nucleotide binding and/or hydrolysis (13). Jones and George (13) provide a convincing theoretical argument in support of a head to tail dimer of HisP in which the nucleotide-binding sites are buried between the monomers, and each monomer contributes residues to both nucleotide-binding sites. The proposed dimer interface, while different from the dimer seen in the crystal structure of HisP (45), is strikingly similar to a recently published dimer of the RAD50 catalytic domain (RAD50cd), an ABC protein involved in DNA double strand break repair (25). ATP promotes the association of two inactive Rad50cd proteins by binding to the signature motif (or LSGGQ) of one monomer and the P-loop of the opposite monomer to complete the active site, thereby activating the ATPase activity (25). The dimer interface seen in the crystal structure of MalK also positions the nucleotide-binding site between the two monomers, although the specific residues contributed to the nucleotide-binding site by the second subunit are not those of the LSGGQ motif (46). In either case, our data are readily interpretable by assuming that ATP is bound between the two MalK subunits in MalFGK2 and that the ATPase activity of the transport complex is regulated by MalK subunit association and dissociation. The decreased solvent accessibility of the P-loop that is associated with activation of the MalFGK2 ATPase, either by MBP or by the BPI mutations, may be the result of the nucleotide-binding site becoming more buried in the MalK dimer interface. Activation of the ATPase activity of the MalK subunit could be achieved if residues on one subunit are required to complete the nucleotide-binding site on the second subunit, and the role of the MBP is to bring the two subunits into closer proximity (Fig. 7). Likewise, the BPI mutations in MalF may activate the ATPase activity of MalFGK2 in the absence of MBP by moving the MalK subunits closer together, explaining why the conformation of the BPI complex more closely resembles the transition state than the ground state of the WT transporter. A stable repositioning of key residues in the second subunit may also account for the increased affinity of the BPI complexes for ATP. Because of the symmetry inherent in a dimer of MalK or of RAD50cd, association and dissociation would affect both nucleotide-binding sites equally (Fig. 7) (25), and we propose that it is this gross conformational change that we are detecting with MIANS at Cys-40. These data provide the first biochemical evidence in support of a model of activation of an intact ABC transporter based on subunit association, as suggested by new structural information. This interpretation should be treated with caution until further corroborating evidence is obtained to define the position of the nucleotide-binding sites within the tetrameric complex.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Model of MalFGK2 ATPase activation by MalK subunit dimerization. Based on the crystal structure of the ABC protein RAD50cd (25), the MalK subunits are placed in a head to tail orientation in the MalFGK2 complex with the nucleotide-binding sites located at the dimer interface. Both MalK subunits contribute residues to each nucleotide-binding site, providing a mechanism for regulating ATPase activity via MalK subunit association and dissociation within the transport complex. Our data suggest that, in the wild type, the MalK subunits are positioned apart, preventing ATP hydrolysis in the absence of MBP, and the residues in the nucleotide-binding site are relatively more accessible to solvent. MBP activates the ATPase activity of the wild type by moving the MalK subunits closer together, rendering the nucleotide-binding sites less accessible to solvent. In a binding protein-independent complex containing the MalF500 mutations, the MalK subunits are positioned closer together, allowing ATP hydrolysis to occur in the absence of MBP.



    ACKNOWLEDGEMENTS

We thank H. A. Shuman for kindly providing the Malk C40G mutant, Steen Pedersen for use of the ISS PC1 photon counting spectro fluorometer, and Jue Chen and Fred Gimble for reading the manuscript.


    FOOTNOTES

* This work was supported in part by United States Public Health Service Grant GM49261 and Robert A. Welch Foundation Grant Q-1391.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported in part by United States Public Health Service Predoctoral Training Grant GM08231.

§ To whom correspondence and reprint requests should be addressed: Dept. of Molecular Virology and Microbiology, MS: BCM 280, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-4552; Fax: 713-798-7375; E-mail: davidson@bcm.tmc.edu.

Published, JBC Papers in Press, January 9, 2001, DOI 10.1074/jbc.M011686200


    ABBREVIATIONS

The abbreviations used are: ABC, ATP-binding cassette; MBP, maltose-binding protein; BPI, binding protein-independent; WT, wild-type; MIANS, 2-(4'-maleimidoanilino)naphthalene-6-sulfonic acid; dodecyl maltoside, n-dodecyl beta -D-maltoside; DTT, dithiothreitol; beta -ME, beta -mercaptoethanol; DPX, p-xylene-bispyridinium bromide; PAGE, polyacrylamide gel electrophoresis; NEM, N-ethylmaleimide.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Higgins, C. (1990) Res. Microbiol. 141, 353-360[Medline] [Order article via Infotrieve]
2. Holland, I. B., and Blight, M. A. (1999) J. Mol. Biol. 293, 381-399[CrossRef][Medline] [Order article via Infotrieve]
3. Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. G. (1986) Cell 47, 381-389[Medline] [Order article via Infotrieve]
4. Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., Drumm, M. L., Iannuzzi, M. C., Collins, F. S., and Tsui, L. C. (1989) Science 245, 1066-1073[Medline] [Order article via Infotrieve]
5. Davidson, A. L., and Nikaido, H. (1990) J. Biol. Chem. 265, 4254-4260[Abstract/Free Full Text]
6. Davidson, A. L., and Nikaido, H. (1991) J. Biol. Chem. 266, 8946-8951[Abstract/Free Full Text]
7. Treptow, N. A., and Shuman, H. A. (1985) J. Bacteriol. 163, 654-660[Medline] [Order article via Infotrieve]
8. Spurlino, J. C., Lu, G. Y., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5202-5219[Abstract/Free Full Text]
9. Sharff, A. J., Rodseth, L. E., Spurlino, J. E., and Quiocho, F. A. (1992) Biochemistry 31, 10657-10663[Medline] [Order article via Infotrieve]
10. Davidson, A. L., Shuman, H. A., and Nikaido, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2360-2364[Abstract]
11. Chen, J., Sharma, S., Quiocho, F. A., and Davidson, A. L. (2001) Proc. Natl. Acad. Sci. U. S. A., in press
12. Sharma, S., and Davidson, A. L. (2000) J. Bacteriol. 182, 6570-6576[Abstract/Free Full Text]
13. Jones, P. M., and George, A. M. (1999) FEMS Microbiol. Lett. 179, 187-202[CrossRef][Medline] [Order article via Infotrieve]
14. Davidson, A. L., Shuman, H. A., and Nikaido, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2360-2364[Abstract]
15. Gupte, S. S., and Lane, L. K. (1979) J. Biol. Chem. 254, 10362-10369[Medline] [Order article via Infotrieve]
16. Haugland, R. P. (1983) in Excited States of Biopolymers (Steiner, R. F., ed) , pp. 41-42, Plenum Publishing Corp., New York
17. Hiratsuka, T. (1992) J. Biol. Chem. 267, 14941-14948[Abstract/Free Full Text]
18. Liu, R., and Sharom, F. J. (1996) Biochemistry 35, 11865-11873[CrossRef][Medline] [Order article via Infotrieve]
19. Liu, R., and Sharom, F. J. (1997) Biochemistry 36, 2836-2843[CrossRef][Medline] [Order article via Infotrieve]
20. Wu, J., and Kaback, H. R. (1994) Biochemistry 33, 12166-12171[Medline] [Order article via Infotrieve]
21. Wu, J., Frillingos, S., and Kaback, H. R. (1995) Biochemistry 34, 8257-8263[Medline] [Order article via Infotrieve]
22. Gardella, D. T., and Susskind, M. M. (1988) Genetics 120, 319-327[Abstract/Free Full Text]
23. Davidson, A. L., and Sharma, S. (1997) J. Bacteriol. 179, 5458-5464[Abstract]
24. Panagiotidis, C. H., Reyes, M., Sievertsen, A., Boos, W., and Shuman, H. A. (1993) J. Biol. Chem. 268, 23685-23696[Abstract/Free Full Text]
25. Hopfner, K. P., Karcher, A., Shin, D. S., Craig, L., Arthur, L. M., Carney, J. P., and Tainer, J. A. (2000) Cell 101, 789-800[Medline] [Order article via Infotrieve]
26. Liu, C. E., Liu, P. Q., and Ames, G. F. L. (1997) J. Biol. Chem. 272, 21883-21891[Abstract/Free Full Text]
27. Davidson, A. L., Laghaeian, S. S., and Mannering, D. E. (1996) J. Biol. Chem. 271, 4858-4863[Abstract/Free Full Text]
28. Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , pp. 260-275, Plenum Publishing Corp., New York
29. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
30. Schaffner, W., and Weissmann, C. (1973) Anal. Biochem. 56, 502-514[Medline] [Order article via Infotrieve]
31. Dassa, E., and Hofnung, M. (1985) EMBO J. 4, 2287-2293[Abstract]
32. Froshauer, S., and Beckwith, J. (1984) J. Biol. Chem. 259, 10896-10903[Abstract/Free Full Text]
33. Dahl, M. K., Francoz, E., Saurin, W., Boos, W., Manson, M. D., and Hofnung, M. (1989) Mol. Gen. Genet. 218, 199-207[Medline] [Order article via Infotrieve]
34. Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951[Medline] [Order article via Infotrieve]
35. Morbach, S., Tebbe, S., and Schneider, E. (1993) J. Biol. Chem. 268, 18617-18621[Abstract/Free Full Text]
36. Hunke, S., Dose, S., and Schneider, E. (1995) Biochem. Biophys. Res. Commun. 216, 589-594[CrossRef][Medline] [Order article via Infotrieve]
37. Hunke, S., and Schneider, E. (1999) FEBS Lett. 448, 131-134[CrossRef][Medline] [Order article via Infotrieve]
38. Ksenzenko, M. Y., Kessel, D. H., and Rosen, B. P. (1993) Biochemistry 32, 13362-13368[Medline] [Order article via Infotrieve]
39. Manson, M. D., Boos, W., Bassford, P. J., Jr., and Rasmussen, B. A. (1985) J. Biol. Chem. 260, 9727-9733[Abstract/Free Full Text]
40. Dean, D. A., Hor, L. I., Shuman, H. A., and Nikaido, H. (1992) Mol. Microbiol. 6, 2033-2040[Medline] [Order article via Infotrieve]
41. Covitz, K.-M. Y., Panagiotidis, C. H., Reyes, M., Treptow, N. A., and Shuman, H. A. (1994) EMBO J. 13, 1752-1759[Abstract]
42. Senior, A. E., and Bhagat, S. (1998) Biochemistry 37, 831-836[CrossRef][Medline] [Order article via Infotrieve]
43. Boos, W., and Lucht, J. M. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C. , Curtiss, R., III , Ingraham, J. L. , Lin, E. C. C. , Low, K. B. , Magasanik, B. , Reznikoff, W. S. , Riley, M. , Schaechter, M. , and Umbarger, H. E., eds) , pp. 1197-1198, American Society for Microbiology, Washington, D. C.
44. Fersht, A. (1985) Enzyme Structure and Mechanism , 2nd Ed. , pp. 311-346, W. H. Freeman & Co., New York
45. Hung, L. W., Wang, I. X., Nikaido, K., Liu, P. Q., Ames, G. F., and Kim, S. H. (1998) Nature 396, 703-707[CrossRef][Medline] [Order article via Infotrieve]
46. Diederichs, K., Diez, J., Greller, G., Muller, C., Breed, J., Schnell, C., Vonrhein, C., Boos, W., and Welte, W. (2000) EMBO J. 19, 5951-5961[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.